Clinical trial
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With…
NCT00028158 · MediGene, Industry · Completed
Key facts
| NCT number | NCT00028158 |
|---|---|
| Title | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer |
| Official title | An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma |
| Lead sponsor | MediGene, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Astrocytoma, Glioblastoma |
| Intervention type | Drug |
| Interventions | G207, an oncolytic virus |
| Enrollment | 65 |
| Start date | Dec 1, 2001 |
| Completion | Oct 1, 2003 |
| First posted | Dec 18, 2001 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: